PGEN

Precigen, Inc

$4.30

-5.29%
Nov 16, 2026
Bobby Quantitative Model
Precigen, Inc. is a commercial-stage biopharmaceutical company developing precision gene and cell therapies across immuno-oncology, autoimmune disorders, and infectious diseases, built on proprietary platforms including AdenoVerse immunotherapy, UltraCAR-T, and the UltraPorator manufacturing device, with a clinical pipeline spanning PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007 and reportable segments in Biopharmaceuticals and Exemplar. With only 47 employees and a roughly $1.3-1.8 billion market capitalization, Precigen is best characterized as a small-cap, platform-driven clinical-stage biotech whose valuation hinges on pipeline execution rather than commercial scale, making it a high-conviction, binary-outcome name rather than a diversified healthcare compounder. The investor narrative has shifted dramatically over the past year: a Q3 2026 print showing $74.1 million in quarterly revenue, $35.8 million of net income, and 91.2% gross margin has reframed the story from cash-burning science project toward a company with a genuine revenue-generating product line, while the stock's violent 38% one-month drawdown after an October peak reflects intense debate over whether that revenue is durable or lumpy. Recent coverage has also positioned PGEN within the low-beta, defensive healthcare cohort favored during rate-hike fears, adding a macro-rotation angle to an otherwise idiosyncratic biotech thesis.

People also watch

Vertex Pharmaceuticals

Vertex Pharmaceuticals

VRTX

Analysis
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

REGN

Analysis
Moderna

Moderna

MRNA

Analysis
BeOne Medicines Ltd. American Depositary Shares

BeOne Medicines Ltd. American Depositary Shares

ONC

Analysis
Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc. Common Stock

RVMD

Analysis

BobbyInvestment Opinion: Should I buy PGEN Today?

Rating: Hold (speculative, high-risk). The core thesis is that Precigen has genuinely transformed from a cash-burning clinical-stage platform into a revenue-generating commercial entity — Q3 2026 revenue of $74.15 million, 91.22% gross margin, $35.77 million net income, and +$11.45 million free cash flow — but at a 131.52x price-to-sales ratio and 60.91x price-to-book, the market has already capitalized a near-flawless forward ramp, leaving an unfavorable risk/reward for new capital at $4.54. The unanimous but thin analyst cohort (2 analysts: HC Wainwright Buy, Citizens Market Outperform) with consensus 2027 EPS of $1.455 and revenue of ~$1.0 billion anchors the bullish case, but with no explicit price targets in the dataset the implied upside cannot be quantified, which itself is a reason for caution.

Supporting evidence cuts both ways. On the positive side, revenue grew 24.38% year-over-year and sequentially from $23.25 million (Q1) to $54.98 million (Q2) to $74.15 million (Q3), gross margin held at 91.22%, operating margin reached 52.13%, and Q3 free cash flow turned positive at +$11.45 million against a trailing -$74.92 million. On the negative side, the trailing picture remains loss-making (EPS -$0.197, net margin -25.88%, ROE -11.99%), cash stood at only $14.96 million, debt-to-equity is 4.70, and interest expense of ~$3.0 million per quarter consumes roughly 8% of quarterly revenue. The 131.52x PS multiple sits in the middle-to-upper portion of a historical 25x-490x band, meaning the re-rating has largely already happened and further upside depends on earnings delivery rather than multiple expansion.

Three risks could invalidate the thesis: (1) revenue durability — if Q4 2026 shows a sequential decline or discloses that Q3 product revenue was a one-time recognition event, the $1.0 billion 2027 consensus collapses; (2) valuation compression — a reset toward the low end of the historical PS band would be severe given the 60.91x book multiple versus 2.4-9x in 2022-2024; (3) financing/liquidity — $14.96 million cash against a trailing -$74.92 million FCF leaves little buffer if the ramp stalls. This Hold would upgrade to Buy if Q4 2026 confirms revenue at or above the ~$74 million run-rate and PS compresses below ~80x on forward sales, and would downgrade to Sell on any sequential revenue decline or a break below the $4.22 November low toward the $3.57 June low. Verdict: overvalued relative to peers (5-15x PS typical for commercial-stage biotech) and to its own 2022-2024 book multiples, but fairly valued only if the forward $1.0 billion revenue estimate is achieved — a binary bet, not a value entry.

Sign up to view all

PGEN 12-Month Price Forecast

The forward view is genuinely balanced: the fundamental inflection is real and recent (three consecutive quarters of sequential revenue growth to $74.15 million, 91.22% gross margin, positive Q3 free cash flow), but the valuation already discounts a near-flawless path to the ~$1.0 billion 2027 revenue consensus, and the 38% one-month collapse shows the market is actively repricing that risk. With only two covering analysts and no explicit price targets, the bullish consensus provides direction but not a quantified floor, while the $14.96 million cash balance and 4.70 debt-to-equity leave little margin for a revenue stumble. I would upgrade to bullish if Q4 2026 confirms recurring revenue at or above the Q3 run-rate and the stock reclaims the $6.90-7.00 resistance, and downgrade to bearish on any sequential revenue decline or a decisive break below the $4.22 November low. Until then, the risk/reward at $4.54 is roughly symmetric, warranting a neutral stance with position sizing appropriate to a binary-outcome small-cap biotech.

Historical Price
Current Price $4.30
Average Target $4.30
High Target $4.94
Low Target $3.65

Wall Street consensus

Coverage is thin, with only 2 analysts contributing estimates, and the institutional ratings history shows a persistently bullish but narrow cohort: HC Wainwright has reiterated Buy repeatedly (most recently August 2026), Citizens has maintained Market Outperform (most recently November 5, 2026), and JMP Securities last acted with Market Outperform in August 2025. The consensus is unambiguously bullish in direction — no Hold or Sell ratings appear in the record — but the small number of covering firms means the signal strength is limited and the stock lacks the institutional sponsorship that broad coverage provides. Consensus revenue estimates of roughly $1.0 billion (range $897.9 million to $1.11 billion) and EPS estimates averaging $1.455 imply the Street expects a transformational 2027, far above the current ~$74 million quarterly run-rate.

The target range is wide in relative terms: estimated EPS spans $1.262 to $1.664 (a roughly 32% spread around the $1.455 average) and revenue estimates span $897.9 million to $1.11 billion (a roughly 24% spread), signaling meaningful uncertainty about the pace of the revenue ramp. The high end assumes successful commercialization and pipeline catalysts driving both sales and multiple expansion, while the low end still assumes a substantial revenue base but with slower conversion and likely margin pressure. With only two analysts and no explicit price targets in the dataset, precise upside cannot be calculated, but the pattern of repeated Buy reiterations alongside a 38% one-month stock decline suggests analysts are anchoring to fundamental estimates while the market reprices risk — a classic setup for either a sharp mean-reversion rally or a credibility test if upcoming quarters fail to validate the $1 billion revenue trajectory.

Drowning in data?

Find the real signal!

Bulls vs Bears: PGEN Investment Factors

The bull case currently rests on stronger hard evidence: a genuine revenue inflection to $74.15 million quarterly, 91.22% gross margins, positive Q3 free cash flow of $11.45 million, and unanimous bullish analyst coverage. The bear case is equally substantive but more forward-looking, centered on whether a 131.5x PS ratio can be justified by revenue that has only existed for a few quarters and whether the 38% one-month collapse signals that the market has already begun repricing that risk. The single most important tension is revenue durability: if Q4 2026 confirms the product line is recurring at or above the Q3 run-rate, the valuation debate shifts from 'is this real' to 'how fast does it scale,' but a sequential decline would validate the bears and expose the stock to a return toward the low end of its historical PS band. On balance, the bulls have the stronger current evidence, but the margin of victory is narrow and entirely dependent on the next one to two quarters of execution.

Bullish

  • Revenue inflection is dramatic and accelerating: Q3 2026 revenue of $74.15 million grew 24.38% year-over-year and followed a sequential ramp from $23.25 million in Q1 to $54.98 million in Q2, versus just $2.92 million in Q3 2025. The product line alone contributed $72.96 million, showing a genuine commercial engine rather than one-off service fees.
  • Profitability swing with 91% gross margins: Q3 2026 net income of $35.77 million (48.24% net margin) and operating income of $38.65 million (52.13% operating margin) mark a sharp reversal from the $146.34 million Q3 2025 loss. Gross margin of 91.22% reflects a high-value product mix that leaves ample room for operating leverage as revenue scales.
  • Positive free cash flow inflection in Q3: Q3 2026 generated +$11.45 million of free cash flow and $11.88 million of operating cash flow, a critical turn from the trailing -$74.92 million FCF. This is the single most important fundamental data point because it suggests the company may be approaching self-funding status.
  • Unanimous bullish analyst coverage: Both covering analysts (HC Wainwright Buy, Citizens Market Outperform) carry bullish ratings with no Hold or Sell in the record, and consensus 2027 EPS of $1.455 and revenue of ~$1.0 billion imply a transformational ramp. The 32% EPS estimate spread signals uncertainty, but the direction of revisions has been consistently positive.

Bearish

  • Valuation is extreme at 131.5x sales: The PS ratio of 131.52x is extraordinary even for biotech, where commercial-stage names typically trade at 5-15x, and price-to-book of 60.91x sits near the top of its multi-year range versus 2.4-9x in 2022-2024. The market is pricing near-flawless execution with little room for multiple expansion.
  • Revenue durability is unproven and lumpy: The step-function from $2.92 million to $74.15 million in a single year is not a smooth compounding curve, and the 38.27% one-month collapse after the October peak reflects investor doubt about recurrence. If the product revenue is a one-time recognition event rather than a recurring base, the entire forward $1.0 billion estimate collapses.
  • Trailing fundamentals remain negative: Trailing EPS of -$0.197, net margin of -25.88%, operating margin of -11.01%, and ROE of -11.99% show the company is only a few quarters removed from loss-making status. Trailing free cash flow of -$74.92 million and a $14.96 million cash balance mean financing risk has not disappeared.
  • Severe momentum breakdown and volatility: The stock is down 38.27% in one month and 25.57% in three months, underperforming SPY by 36.01% and 22.74% respectively, with a -50.7% max drawdown. The failed push toward the $8.56 September high and the break below $6.90-7.00 resistance signal a blow-off top unwinding rather than a simple pullback.

PGEN Technical Analysis

PGEN is in a recovery-turned-rollover pattern: the stock is up 17.62% over the trailing year and 6.07% year-to-date, but the current price of $4.54 sits only about 53% of the way through its 52-week range, having peaked near $8.56 in late September 2026 and bottomed near $3.57 in early June 2026. That positioning — mid-range after a failed push toward the highs — signals momentum has broken rather than that the stock is either overextended or a clean falling knife, and the -50.7% max drawdown underscores how violently this name can round-trip. The 52-week high of roughly $8.56 versus the $4.54 close means the stock has surrendered about 47% from its peak, a classic post-catalyst deflation in a small-cap biotech.

Short-term momentum is decisively negative and diverging sharply from the longer-term trend: the 1-month change is -38.27% and the 3-month change is -25.57%, versus a still-positive 1-year gain of 17.62%. That divergence — a positive annual return paired with a collapse in the last quarter — is the signature of a blow-off top unwinding rather than a simple pullback, and the relative strength figures confirm it: -36.01% versus SPY over one month and -22.74% over three months, against a modest +5.35% one-year relative gain. The most recent sessions show stabilization attempts (from $4.22 on Nov 5 to $4.54 on Nov 13, a bounce of roughly 7.6%), but with volume data unavailable and the stock still down from $6.94 on Oct 30, the bounce looks corrective rather than a confirmed reversal.

Key technical levels are well defined: support sits at the June 2026 low around $3.57, with secondary support near the $4.22 November low, while resistance is the $8.56 September high, with an intermediate ceiling around $6.90-7.00 where the stock repeatedly stalled in August and October. A decisive break below $4.22 would target the $3.57 area and signal that the post-earnings sellers remain in control, whereas reclaiming $7.00 would be the first evidence of a durable bottom. Beta is not available in the provided data, but the -50.7% max drawdown and the 38% one-month decline imply volatility far in excess of the market, warranting materially smaller position sizing than a typical equity allocation.

Beta

—

—

Max Drawdown

-50.7%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

-11.3%

Cumulative gain past year

PeriodPGEN ReturnS&P 500
1m-32.7%-3.0%
3m-36.3%-3.6%
6m+0.7%-0.2%
1y-11.3%+10.1%
ytd+0.5%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

PGEN Fundamental Analysis

The revenue trajectory has inflected violently upward: Q3 2026 revenue of $74.15 million grew 24.38% year-over-year and followed Q2 2026 revenue of $54.98 million and Q1 2026 revenue of $23.25 million, a sequential ramp that dwarfs the $4.57 million booked in Q4 2025 and the $2.92 million in Q3 2025. Segment data shows the Product line at $72.96 million versus just $1.19 million in Service revenue, meaning essentially the entire top line is product-driven and highly concentrated. The critical caveat is that this is a step-function, not a smooth compounding curve — the year-ago quarters were near-zero — so the investment case rests on whether the new product revenue base is recurring and sustainable rather than a one-time recognition event.

Profitability has swung from deeply negative to positive: Q3 2026 net income was $35.77 million with a 91.22% gross margin and a 48.24% net margin, versus a Q3 2025 net loss of $146.34 million and a Q1 2026 loss of $7.93 million. The gross margin expansion from 87.63% in Q1 2026 to 94.90% in Q2 and 91.22% in Q3 reflects a high-value product mix, while operating income of $38.65 million (52.13% operating margin) in Q3 shows the cost base — $6.63 million R&D and $22.36 million G&A — is now comfortably covered by revenue. Still, the trailing metrics remain negative (EPS of -$0.197, net margin of -25.88%, operating margin of -11.01%), so the company is only a few quarters removed from loss-making status and the durability of profitability is unproven.

The balance sheet is liquid but levered: the current ratio is 3.09, cash stood at $14.96 million at Q3 2026, and debt-to-equity is 4.70, a high figure that reflects a small equity base more than crushing leverage. Free cash flow is -$74.92 million on a trailing basis, though Q3 2026 alone generated +$11.45 million of FCF and $11.88 million of operating cash flow after several cash-burning quarters, and ROE of -11.99% still reflects the trailing loss. The company is not yet self-funding on a trailing basis and remains sensitive to financing conditions, but the Q3 cash inflection is the single most important fundamental data point in the set.

Quarterly Revenue

$74148000.0B

2026-09

Revenue YoY Growth

N/A

YoY Comparison

Gross Margin

91.2%

Latest Quarter

Free Cash Flow

$-74920000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Product
Service

Open an Account, get $2 TSLA now!

Valuation Analysis: Is PGEN Overvalued?

Because trailing net income is negative (EPS of -$0.197, trailing PE of -2.96), the PE ratio is not meaningful and I am leading with the price-to-sales ratio of 131.52x, cross-checked against the price-to-book of 60.91x and the negative EV/EBITDA of -5.51x. The forward PE of -0.0148 is also unusable, but the analyst consensus EPS estimate of $1.455 and revenue estimate of roughly $1.0 billion imply the market expects a dramatic earnings inflection that the trailing multiples cannot capture — the gap between trailing losses and forward profitability is the entire valuation debate.

On a peer basis, a 131.5x PS ratio is extraordinary even for biotechnology, where high-growth commercial-stage names typically trade in the 5-15x range and clinical-stage platforms often trade on pipeline value rather than sales. The premium is partially explained by the fact that the revenue base is newly established and the market is capitalizing a forward run-rate rather than trailing sales, but it also means the stock is priced for near-flawless execution. The 60.9x price-to-book and 37.05% gross margin in the valuation dataset (versus the 91.22% quarterly gross margin) highlight inconsistent data vintages, reinforcing that the multiples should be treated as directional rather than precise.

Historically, PGEN's PS ratio has ranged from roughly 25x (Q3 2022) to over 490x (Q2 2025), and the current 131.5x sits in the middle-to-upper portion of that band, while the price-to-book of 60.9x is near the top of its multi-year range versus 2.4-9x in 2022-2024. That tells us the market has already re-rated the equity substantially on the revenue inflection, leaving less room for multiple expansion and more dependence on earnings delivery; a return to the low end of the historical PS band would imply severe downside if growth disappoints.

PE

-3.0x

Latest Quarter

vs. Historical

N/A

5-Year PE Range 17x~59x

vs. Industry Avg

29.3x

Industry PE ~29.3x*

EV/EBITDA

-5.5x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks are concentrated in revenue concentration and cash runway. Essentially the entire top line is product-driven ($72.96 million of $74.15 million in Q3), so a single product or contract disruption would be catastrophic, and the step-function nature of the ramp means there is no established recurring base to cushion a miss. Trailing free cash flow remains -$74.92 million despite the Q3 positive inflection, cash stood at only $14.96 million at quarter-end, and debt-to-equity of 4.70 leaves the company sensitive to financing conditions if the revenue ramp stalls. Interest expense of roughly $3.0 million per quarter further erodes the thin profitability, and trailing EPS of -$0.197 confirms the company is not yet sustainably profitable.

Market and competitive risks center on valuation compression and sector rotation. At 131.52x sales and 60.91x book, PGEN trades at a massive premium to the 5-15x PS range typical of commercial-stage biotech, meaning any deceleration in growth would trigger a violent multiple reset; the stock's historical PS band of 25x to 490x shows how far it can fall. The 38.27% one-month decline and -36.01% relative underperformance versus SPY demonstrate how quickly sentiment can reverse in a thin-coverage name with only 2 analysts. While recent coverage framed PGEN as a low-beta defensive healthcare holding during rate-hike fears, that positioning is fragile — a rotation back into cyclicals or a rate-cut regime would remove the defensive bid, and competitive gene-therapy readouts (such as uniQure's waning-efficacy data) remind investors that binary clinical risk is never far away in this sector.

The worst-case scenario is a Q4 2026 print showing sequential revenue decline or a disclosure that Q3 product revenue was a one-time recognition event, which would simultaneously invalidate the $1.0 billion 2027 consensus and force a multiple reset from 131.5x toward the low end of its historical PS band. In that chain of events, the stock would likely retest the June 2026 low of $3.57 and potentially the -50.7% max drawdown level, implying roughly -21% from the current $4.54 to the 52-week low and a realistic downside of -30% to -45% if the $3.57 support fails. A break below the November low of $4.22 would be the first technical confirmation that sellers remain in control, and with no explicit analyst price targets to anchor a floor, the downside is defined primarily by the 52-week range rather than by fundamental valuation support.

FAQ

The most severe risk is revenue durability: essentially the entire top line is product-driven ($72.96 million of $74.15 million in Q3), and the step-function from $2.92 million a year earlier means there is no established recurring base — a sequential Q4 decline would invalidate the $1.0 billion 2027 consensus. Second is valuation compression: at 131.52x sales and 60.91x book, any growth deceleration could trigger a violent reset toward the low end of the historical 25x-490x PS band. Third is financing and liquidity: cash stood at only $14.96 million against trailing free cash flow of -$74.92 million, with debt-to-equity of 4.70 and roughly $3.0 million of quarterly interest expense, leaving little buffer if the ramp stalls. Fourth is market and sector risk: the stock is down 38.27% in one month and underperformed SPY by 36.01%, and its low-beta defensive positioning could unwind if rate-hike fears fade, while competitive gene-therapy setbacks (such as uniQure's waning-efficacy data) can sour sentiment on the whole modality.

The 12-month outlook splits into three scenarios. The base case (50% probability, $4.22-$6.00) assumes revenue proves durable but lumpy, with Q4 2026 landing between roughly $50 million and $74 million, gross margin above 85%, and no new equity raise, leaving the stock range-bound between the November low and the $6.90-7.00 resistance. The bull case (25%, $7.00-$8.56) requires Q4 revenue at or above the ~$74 million run-rate plus pipeline catalysts or broader analyst coverage, re-rating the stock back toward its September 2026 high. The bear case (25%, $3.57-$4.22) is a sequential revenue decline or disclosure that Q3 product revenue was a one-time recognition event, forcing a multiple reset and a retest of the June low. The base case is most likely, and its key assumption is that the Q3 revenue base is recurring rather than a single recognition event.

PGEN looks overvalued on trailing metrics and fairly valued only if the forward consensus is achieved. Trailing PE is negative (-2.96) and forward PE is unusable (-0.0148), so the meaningful gauge is the 131.52x price-to-sales ratio, which is extraordinary versus the 5-15x range typical of commercial-stage biotech. The 60.91x price-to-book sits near the top of its multi-year range versus 2.4-9x in 2022-2024, and the current PS sits in the middle-to-upper portion of its own historical 25x-490x band. That means the market has already re-rated the equity substantially on the revenue inflection, leaving less room for multiple expansion and more dependence on earnings delivery. The valuation implies the market expects the ~$1.0 billion 2027 revenue and $1.455 EPS consensus to materialize; if it does, the multiple compresses on forward sales rather than price falling, but if it slips, the downside toward the low end of the historical PS band is severe.

From a risk/reward perspective, PGEN at $4.54 offers a roughly symmetric setup rather than a compelling entry. The bull case is real — Q3 2026 revenue of $74.15 million, 91.22% gross margin, and +$11.45 million of free cash flow mark a genuine inflection — but the 131.52x price-to-sales ratio already prices in near-flawless execution toward the ~$1.0 billion 2027 revenue consensus. The biggest downside risk is that Q3 product revenue proves lumpy or one-time, which would force a multiple reset and a retest of the $4.22 November low or the $3.57 June low, roughly -21% to -50% from current levels. With only 2 covering analysts and no explicit price targets, the unanimous bullish consensus cannot be translated into quantified upside. It is a reasonable speculative buy only for risk-tolerant investors with small position sizing who want binary exposure to the revenue-durability thesis; for most investors, waiting for Q4 2026 confirmation is the higher-probability approach.

PGEN is better suited to a patient, risk-tolerant long-term holding than to short-term trading, but only with small position sizing. The company is in an early commercial-stage growth phase with only 47 employees and a roughly $1.3-1.8 billion market cap, and its earnings visibility is low — the entire forward case rests on a 2027 consensus that is far above the current ~$74 million quarterly run-rate. Volatility is extreme: a -50.7% max drawdown and a 38.27% one-month decline imply far more risk than a typical equity, and the stock pays no dividend (0% yield, 0 payout ratio), so there is no income cushion. Short-term trading is treacherous given the binary reaction to quarterly prints and thin 2-analyst coverage. A concrete suggested minimum holding period is 12-18 months, spanning at least two to three quarterly reports to confirm revenue recurrence, with position sizing appropriate to a binary-outcome small-cap biotech.